Inactive Instrument

Highlights biOasis Technologies Inc Toronto S.E.

Equities

BTI

CA09064N1033

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Bioasis Technologies Inc. Announces Terminating the Non-Exclusive Research Collaboration and Licensing Agreement with Chiesi Farmaceutici S.P.A	23-06-20	CI
Midatech Pharma plc cancelled the acquisition of Bioasis Technologies Inc..	23-01-22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	23-01-19	CI
BiOasis Technologies, Inc. and Midatech Pharma plc Merger Call	22-12-20	FA
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc	22-12-13	GL
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc	22-12-13	GL
Midatech Pharma plc entered into a definitive agreement to acquire Bioasis Technologies Inc. from The Lind Partners, LLC and others for $5.5 million.	22-12-12	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022	22-10-28	CI
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022	22-07-29	CI
Bioasis Technologies Buys Phase 2 Ready Rare Orphan EGF Assets From Norwegian Company	22-06-16	MT
Bioasis Technologies Inc. Reports Earnings Results for the Full Year Ended February 28, 2022	22-06-14	CI
Bioasis Technologies and Neuramedy of South Korea Enter into Research Collaboration and License Agreement	22-05-11	MT
Bioasis Technologies Inc. and Neuramedy Co Ltd Enter into Research Collaboration and License Agreement	22-05-10	CI
Bioasis Technologies Inc. Enters Research Collaboration with Janssen Biotech, Inc	22-04-11	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2021	22-01-20	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2021	21-10-28	CI
Bioasis Technologies Brief: nnounces Allowance of Japanese Patent Application in Japan Relating to Fusion Protein Comprising Iduronate-2-sulfatase	21-08-09	MT
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2021	21-07-29	CI
Bioasis Technologies Inc. Announces Positive Results from Efficacy Study of xB3™-IL-1RA in Model of Multiple Sclerosis	21-07-07	CI
Bioasis Technologies : Names New CFO	21-07-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights biOasis Technologies Inc Toronto S.E.

Equities

BTI

CA09064N1033

Highlights

Filters